Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04750941 · ClinicalTrials.gov registry record · Phase 2
Study of Copanlisib and Ketogenic Diet
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04750941: Clinical Trial Phase 2 study, sponsored by Columbia University.
NCT04750941 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04750941, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documented activating mutation in PIK3CA or loss of phosphatase and tensin homolog (PTEN).
Primary Outcome
ORR will be determined from the number of individuals with a complete response (CR) and number of individuals with a partial response (PR)
Interventions
- OTHER Ketogenic Diet
- DRUG Copanlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2023-06-09 |
| Phase | Phase 2 |
Why NCT04750941 stopped before completion
NCT04750941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Ketogenic Diet is the first listed.
NCT04750941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04750941 about?
NCT04750941 is a clinical study titled "Study of Copanlisib and Ketogenic Diet". This is a multicenter, open label, pilot phase II study of the PI3K inhibitor copanlisib in combination with a ketogenic diet in the treatment of patients with one of the following malignancies: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documen...
What is the current status of trial NCT04750941?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-02-10. Estimated completion is 2023-06-09.
What interventions are being tested in trial NCT04750941?
The interventions under investigation include: Ketogenic Diet (OTHER), Copanlisib (DRUG).
Who is sponsoring clinical trial NCT04750941?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04750941's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI